SEC Tracker
Get the app

Repligen RGEN

Repligen FY 2023: net income $35.6M, down 81%; diluted EPS $0.63

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Repligen reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income$35.6M−81% from $186.0M in FY 202210-K/A income statement, on EDGAR
  2. Diluted EPS$0.63−81% from $3.24 in FY 202210-K/A income statement, on EDGAR
  3. Cash and cash equivalents$751.3M+44% from $523.5M in FY 202210-K/A balance sheet, on EDGAR
  4. Cash from operations$113.9M−34% from $172.1M in FY 202210-K/A cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Repligen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025